139755-99-0

Basic information

• Product Name: 1-METHYL-3-PROPYLPYRAZOLE-5-CARBOXYLIC ACID
• Synonyms: TIMTEC-BB SBB010494;ASINEX-REAG BAS 02107705;CHEMBRDG-BB 4402460;2-METHYL-5-PROPYL-2H-PYRAZOLE-3-CARBOXYLIC ACID;1-METHYL-3-PROPYL-1H-PYRAZOLE-5-CARBOXYLIC ACID;1-METHYL-3-PROPYLPYRAZOLE-5-CARBOXYLIC ACID;1-METHYL-3-PROPYL-5-PYRAZOLE CARBOXYLIC ACID;2-Methyl-5-propyl-2H-pyrazole-3-carboxboxylic acid
• CAS NO: 139755-99-0
• Molecular Formula: C₈H₁₂N₂O₂
• Molecular Weight: 168.19
• Product Categories: GLYCINESCAFFOLD;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 139755-99-0.mol
• Article Data: 14

Chemical Properties

• Melting Point: 150-154 °C
• Boiling Point: 330.274 °C at 760 mmHg
• Flash Point: 153.544 °C
• Appearance: /
• Density: 1.192 g/cm³
• Vapor Pressure: 6.74E-05mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Sightly), Methanol (Slightly)
• PKA: 3.10±0.25(Predicted)
• CAS DataBase Reference: 1-METHYL-3-PROPYLPYRAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-3-PROPYLPYRAZOLE-5-CARBOXYLIC ACID(139755-99-0)
• EPA Substance Registry System: 1-METHYL-3-PROPYLPYRAZOLE-5-CARBOXYLIC ACID(139755-99-0)

Safety Data

• Statements: 20/21/22
• Safety Statements: 3/9-24/25-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 139755-99-0(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

Intermediate in the production of Sildenafil and respective analogs.

InChI:InChI=1/C8H12N2O2/c1-3-4-6-5-7(8(11)12)10(2)9-6/h5H,3-4H2,1-2H3,(H,11,12)/p-1

Upstream product

• 92945-27-2 ethyl 3-propyl-1H-pyrazole-5-carboxylate 
• 302-15-8 methylhydrazine sulfuric acid 
• 107-87-9 2-Pentanone 
• 36983-31-0 ethyl 3-butyrylpyruvate 
• 60-34-4 methylhydrazine 
• 133261-07-1 1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester 

Downstream Products

• 139756-02-8 4-amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide 
• 778639-43-3 2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid 2-acetyl-4,6-dichloro-phenyl ester 
• 778639-42-2 2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid 2-acetyl-6-chloro-phenyl ester 
• 778639-46-6 2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid 2-acetyl-4-bromo-phenyl ester 
• 1610875-93-8 1-methyl-3-propyl-5-(2,4,5-trimethoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-(6H)-one 

Relevant articles and documents

Novel pyrrolidine or piperidine derivatives having activity for T-type calcium channel

A pyrrolidine or piperidine compound having activity for T - type calcium channel, wherein the pyrrolidine or piperidine compound of Formula 1 according to the present invention has an excellent antagonistic activity to, T-type calcium channel, and can be used as a preventive or therapeutic agent, for pain diseases, or cancer related to cancer, or cancer such as, epilepsy and,hepatic pain, angina. (by machine translation)

NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT

Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a -(C=O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases.

PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to Pyrazolopyrimidinone compounds as PDE5 inhibitors with better IC50 value, good in vivo efficacy and PK profile and a process for the preparation thereof. The present invention covers the pyrazolo pyrimidinone based compounds that have been designed, synthesized and screened for PDE5 inhibitory activity and its PDE5 inhibitory potential is provided in this invention. These designer compounds have shown nanomolar potency when screened for PDE5 inhibitory activity and also shown better in vivo efficacy. These compounds can be used in the treatment of male erectile dysfunction or in the treatment of impotence.